# A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

> **NCT05668572** · PHASE3 · UNKNOWN · sponsor: **Beijing Health Guard Biotechnology, Inc** · enrollment: 12000 (actual)

## Conditions studied

- Human Papillomavirus Infection

## Interventions

- **BIOLOGICAL:** Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)
- **BIOLOGICAL:** Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®）

## Key facts

- **NCT ID:** NCT05668572
- **Lead sponsor:** Beijing Health Guard Biotechnology, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-05
- **Primary completion:** 2022-07-21
- **Final completion:** 2023-02-23
- **Target enrollment:** 12000 (ACTUAL)
- **Last updated:** 2023-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05668572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05668572, "A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05668572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*